DIAGNOSIS AND PHARMACOTHERAPY OF PELVIC INFLAMMATORY DISEASES IN WOMEN

Abstract

The article is devoted to modern issues of etiology, in particular, the theory of biofilms as the most promising direction of research. Biofilms are most often represented by the association of microorganisms in which they, through coexistence in close contacts, acquire new properties, expressed in an atypical clinical picture. This determines problems of rapid diagnosis and pathogenesis, in which both the local and systemic secondary immunodeficiency state is put in the forefront, autoimmune inflammation and reactions of free radical oxidation. The most typical symptoms and signs of inflammatory diseases of the pelvic organs include, in particular, chronic salpingo-oophoritis - a common nosological item from this group, which has important social and demographic significance, since the most affected group, according to statistics, are women of reproductive age. The emphasis was placed on approaches to diagnosis using not only data from the collected history and physical examination but also methods based on modern instrumental and minimally invasive methods. Special attention was paid to measures aimed at correcting risk factors and preventing this disease, etiotropic therapy with the presentation of a specific scheme of the most rational antibiotic therapy, pathogenetic and symptomatic treatment to alleviate the condition before the eradication of the pathogenic microorganism or their association in the composition of biofilms and cure patients, and correction such unpleasant complications as vaginal dysbiosis, which can develop against a background of powerful antibiotic therapy and is not a measure of inadequate treatment and change of the selected regimen.

Keywords

pelvic inflammatory diseases (PID) / dysbiosis / antibiotic therapy / microflora / women / gynecology / pain in the pelvis

References

[1] Безбах И.В. Применение структурно-резонансной терапии в восстановительном лечении больных хроническим сальпингоофоритом. Журнал Российского общества акушеров-гинекологов. 2006; (3): 26-8.

[2] Владимиров Ю.А. Свободные радикалы и антиоксиданты. Вестник РАМН. 1998; (7): 43-51.

[3] Бакуридзе Э.М., Дубницкая Л.В., Фёдорова Т.А. Реабилитация пациенток с бесплодием после реконструктивно-пластических операций на органах малого таза. Журнал акушерства и женских болезней. 2001; 50 (3): 47-51.

[4] Медведев Б.И., Коваленко В.Л., Казачкова Э.А., Казачков Е.Л. Воспалительные заболевания матки и придатков: патогенез, клинико-морфологическая характеристика, диагностика, лечение. Челябинск: ЧГМА; 2001.

[5] Бухарин О.В. Персистенция патогенных бактерий. М.: Медицина; 1999.

[6] Краснопольский В.И., Буянова С.Н., Щукина Н.А. Гнойно-септические осложнения в акушерстве и гинекологии: патогенез, диагностика и лечебная тактика. Российский вестник акушера-гинеколога. 2007; 7(5): 76-81.

[7] Быковская О.В. Иммуномодулирующая терапия при хронических цервицитах, обусловленных уреа- и микоплазменной инфекцией. Гинекология. 2007; 9 (1): 24-5.

[8] Стрижаков А.Н., Давыдов А.И., Баев О.Р., Буданов П.В. Генитальные инфекции. М.: Династия; 2003.

[9] Болевич С. Аутофагоцитарные свободнорадикальные болезни лёгких. В кн.: Свободные радикалы и болезни человека (научно-практическая конференция). Смоленск; 1999: 113-5.

[10] Sutton M.Y., Sternberg M., Zaidi A., St Louis M.E., Markowitz L.E. Trends in pelvic inflammatory disease hospital discharges and ambulatory visits, United States, 1985-2001. Sex. Transm. Dis. 2005; 32 (12): 778-84.

[11] Haggerty C.L., Gottlieb S.L., Taylor B.D., Low N., Xu F., Ness R.B. Risk of sequelae after Chlamydia trachomatis genital infection in women. J. Infect. Dis. 2010; 201 (Suppl. 2): S134-55.

[12] Chesson H.W., Collins D., Koski K. Formulas for estimating the costs averted by sexually transmitted infection (STI) prevention programs in the United States. Cost. Eff. Resour. Alloc. 2008; 6: 10.

[13] Gottlieb S.L., Berman S.M., Low N. Screening and treatment to prevent sequelae in women with Chlamydia trachomatis genital infection: how much do we know? J. Infect. Dis. 2010; 201 (Suppl. 2): S156-67.

[14] Workowski K.A., Berman S. Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010 [published by Morb. Mortal Wkly Rep. 2011; 60 (1): 18]. MMWR Recomm. Rep. 2010; 59 (RR-12): 1-110.

[15] Soper D.E. Pelvic inflammatory disease. Obstet. Gynecol. 2010; 116 (2 pt 1): 419-28.

[16] Blenning C.E., Muench J., Judkins D.Z., Roberts K.T. Clinical inquiries. Which tests are the most useful for diagnosing PID? J. Fam. Pract. 2007; 56 (3): 216-20.

[17] Simms I., Stephenson J.M., Mallinson H. et al. Risk factors associated with pelvic inflammatory disease. Sex. Transm. Infect. 2006; 82 (6): 452-7.

[18] Gaitán H., Angel E., Diaz R., Parada A., Sanchez L., Vargas C. Accuracy of the five different diagnostic techniques in mild-to-moderate pelvic inflammatory disease. Infect. Dis. Obstet. Gynecol. 2002; 10 (4): 171-80.

[19] Doxanakis A., Hayes R.D., Chen M.Y., et al. Missing pelvic inflammatory disease? Substantial differences in the rate of PSI. Sex. Transm. Infect. 2008; 84 (7): 518-23.

[20] Cottrell B.H. An updated review of evidence to discourage douching. MCN Am. J. Maternal Child Nurs. 2010; 35 (2): 102-7.

RIGHTS & PERMISSIONS

Eco-Vector